Literature DB >> 22469522

The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art.

Mike De Vos1, Valérie Schreiber, Françoise Dantzer.   

Abstract

Poly(ADP-ribose) polymerase (PARP) catalyzed poly(ADP-ribosyl)ation is one of the earliest post-translational modification of proteins detectable at sites of DNA strand interruptions. The considerable recent progress in the science of PARP in the last decade and the discovery of a PARP superfamily (17 members) has introduced this modification as a key mechanism regulating a wide variety of cellular processes including among others transcription, regulation of chromatin dynamics, telomere homeostasis, differentiation and cell death. However, the most extensive studied and probably the best characterized role is in DNA repair where it plays pivotal roles in the processing and resolution of the damaged DNA. Although much of the focus has been on PARP1 in DNA repair, recent advances highlight the emergence of other DNA-dependent PARPs (i.e. PARP2, PARP3 and possibly Tankyrase) in this process. Here we will summarize the recent insights into the molecular functions of these PARPs in different DNA repair pathways in which they emerge as specific actors. Furthermore, the DNA repair functions of PARP1 have stimulated another area of intense research in the field with the development of potent and selective PARP1 inhibitors to promote genome instability and cell death in tumor cells. Their current use in clinical trials have demonstrated potentiation of antitumoral drugs and cytotoxicity in repair deficient tumor cells.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22469522     DOI: 10.1016/j.bcp.2012.03.018

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  193 in total

1.  Discovery of potent 2,4-difluoro-linker poly(ADP-ribose) polymerase 1 inhibitors with enhanced water solubility and in vivo anticancer efficacy.

Authors:  Wen-Hua Chen; Shan-Shan Song; Ming-Hui Qi; Xia-Juan Huan; Ying-Qing Wang; Hualiang Jiang; Jian Ding; Guo-Bin Ren; Ze-Hong Miao; Jian Li
Journal:  Acta Pharmacol Sin       Date:  2017-08-03       Impact factor: 6.150

2.  Mitogen-activated protein kinase-activated protein kinase 2 mediates apoptosis during lung vascular permeability by regulating movement of cleaved caspase 3.

Authors:  Mahendra Damarla; Ahmad R Parniani; Laura Johnston; Hasina Maredia; Leonid Serebreni; Omar Hamdan; Venkataramana K Sidhaye; Larissa A Shimoda; Allen C Myers; Michael T Crow; Eric P Schmidt; Carolyn E Machamer; Matthias Gaestel; Madhavi J Rane; Todd M Kolb; Bo S Kim; Rachel L Damico; Paul M Hassoun
Journal:  Am J Respir Cell Mol Biol       Date:  2014-05       Impact factor: 6.914

3.  Filia Is an ESC-Specific Regulator of DNA Damage Response and Safeguards Genomic Stability.

Authors:  Bo Zhao; Wei-Dao Zhang; Ying-Liang Duan; Yong-Qing Lu; Yi-Xian Cun; Chao-Hui Li; Kun Guo; Wen-Hui Nie; Lei Li; Rugang Zhang; Ping Zheng
Journal:  Cell Stem Cell       Date:  2015-04-30       Impact factor: 24.633

4.  Regulation of mitochondrial poly(ADP-Ribose) polymerase activation by the β-adrenoceptor/cAMP/protein kinase A axis during oxidative stress.

Authors:  Attila Brunyanszki; Gabor Olah; Ciro Coletta; Bartosz Szczesny; Csaba Szabo
Journal:  Mol Pharmacol       Date:  2014-07-28       Impact factor: 4.436

5.  NF-κB-dependent DNA damage-signaling differentially regulates DNA double-strand break repair mechanisms in immature and mature human hematopoietic cells.

Authors:  D Kraft; M Rall; M Volcic; E Metzler; A Groo; A Stahl; L Bauer; E Nasonova; D Salles; G Taucher-Scholz; H Bönig; C Fournier; L Wiesmüller
Journal:  Leukemia       Date:  2015-02-05       Impact factor: 11.528

Review 6.  Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Authors:  Nathan A Berger; Valerie C Besson; A Hamid Boulares; Alexander Bürkle; Alberto Chiarugi; Robert S Clark; Nicola J Curtin; Salvatore Cuzzocrea; Ted M Dawson; Valina L Dawson; György Haskó; Lucas Liaudet; Flavio Moroni; Pál Pacher; Peter Radermacher; Andrew L Salzman; Solomon H Snyder; Francisco Garcia Soriano; Robert P Strosznajder; Balázs Sümegi; Raymond A Swanson; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-26       Impact factor: 8.739

7.  A new sub-pathway of long-patch base excision repair involving 5' gap formation.

Authors:  Jordan Woodrick; Suhani Gupta; Sharon Camacho; Swetha Parvathaneni; Sujata Choudhury; Amrita Cheema; Yi Bai; Pooja Khatkar; Hayriye Verda Erkizan; Furqan Sami; Yan Su; Orlando D Schärer; Sudha Sharma; Rabindra Roy
Journal:  EMBO J       Date:  2017-04-03       Impact factor: 11.598

Review 8.  Nucleotide excision repair in humans.

Authors:  Graciela Spivak
Journal:  DNA Repair (Amst)       Date:  2015-09-10

Review 9.  Multiple interaction partners for Cockayne syndrome proteins: implications for genome and transcriptome maintenance.

Authors:  Maria D Aamann; Meltem Muftuoglu; Vilhelm A Bohr; Tinna Stevnsner
Journal:  Mech Ageing Dev       Date:  2013-04-09       Impact factor: 5.432

10.  Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias.

Authors:  Renu Singh; Shailly Mehrotra; Mathangi Gopalakrishnan; Ivana Gojo; Judith E Karp; Jacqueline M Greer; Alice Chen; Richard Piekarz; Brian F Kiesel; Jogarao Gobburu; Michelle A Rudek; Jan H Beumer
Journal:  Cancer Chemother Pharmacol       Date:  2018-11-20       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.